SCHEMBL4174567

SCHEMBL4174567

O=C(O)c1ccc(-c2nccnc2Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.49
CA9 Q16790 1/20 0.49
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
TSHR P16473 2/20 0.47
ALOX15 P16050 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAP2K4 P45985 3/20 0.45
CDH1 P12830 1/20 0.45
APC P25054 1/20 0.45
CTNNB1 P35222 1/20 0.45
TCF7L2 Q9NQB0 1/20 0.45
ADH5 P11766 1/20 0.45
TP53 P04637 1/20 0.44
NAPRT Q6XQN6 2/20 0.44
MKNK1 Q9BUB5 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5697449 0.80 TRPV1 (0.51) TSHRALOX15KDM4EMAP2K4CDH1
SCHEMBL3874091 0.79 TRPV1 (0.56) RXRARXRBKDM4EADH5MKNK1
SCHEMBL17908089 0.77 NAPRT (0.49) RXRARXRBTSHRALOX15KDM4E
SCHEMBL2904162 0.77 ABCC4 (0.50) RXRARXRBTSHRKDM4EALDH1A1
SCHEMBL11145941 0.76 KDM4E (0.48) ALOX15KDM4EALDH1A1LMNASMN1; SMN2
SCHEMBL3325880 0.76 PDE3B (0.43) KDM4EALDH1A1LMNASMN1; SMN2
SCHEMBL2040773 0.74 FFAR2 (0.47) CA12CA9RXRAKDM4EALDH1A1
SCHEMBL29788291 0.74 FFAR2 (0.47) CA12CA9RXRAKDM4EALDH1A1
SCHEMBL31227325 0.74 LMNA (0.44) KDM4ELMNASMN1; SMN2
SCHEMBL22861594 0.73 TP53 (0.60) CA12CA9RXRARXRBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP disclosed
CN-101128452-B Novel benzimidazole derivatives and pharmaceutical compositions containing the same DAE WOONG PHARMA 2012-11-21 CN disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
CN-101128452-A Novel benzimidazole derivatives and pharmaceutical compositions containing the same DAE WOONG PHARMA (KR) 2008-02-20 CN disclosed
EP-1861387-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2007-12-05 EP disclosed
WO-2006080821-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same TRPV1, TRPA1, BDKRB2 CA12 4401/4885CA9 4080/4885RXRA 2920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.